跳至主要内容
临床试验/IRCT20090117001556N138
IRCT20090117001556N138尚未招募2 期

Investigating the effect of Famotidine on cognitive and behavioral dysfunctions induced by COVID-19: A randomized double blind and placebo controlled clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • History of hospitalization due to COVID-19
  • At least 20 days from the onset of symptoms, and 7 days from the last day of symptoms passed
  • Diagnosis of cognitive impairment (score 23 or less in MMSE test, or score 22 or less in MoCA test)
  • Age between 18-65

排除标准

  • Being psychotic
  • Presence of other psychiatric disorders
  • Using other psychiatric drugs or any drug which can affect cognitive performance
  • History of ECT during past 2 months
  • Presence of thyroid disease
  • Presence of kidney disease
  • Presence of liver disease
  • History of cognitive impairment or dementia
  • Pregnant or lactating women

研究者

相似试验